| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5705290 | Ophthalmology | 2017 | 9 Pages |
Abstract
Ranibizumab did not show a statistically significant influence on new MA development in eyes with neovascular AMD, whether dosed monthly or per TREX regimen. The FCT, SHRM thickness, and hemorrhage at baseline were all significant predictors of new MA.
Keywords
CNVERMASHRMCATTPEDFAFRPESRFAMDFCTChoroidal neovascularizationgeographic atrophyMacular atrophyretinal pigment epitheliumTREXPigment epithelial detachmentage-related macular degenerationVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)fundus autofluorescenceSubretinal fluidsubretinal hyperreflective material
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Nizar S. MD, Mayss MD, Sean BS, Ahmed PhD, SriniVas R. MD, Charles C. MD, PhD,